Product Quality Research for Developing and Assessing Regulatory Submissions for Generic Cyclosporine Ophthalmic Emulsions.

Author: BelenosAvery, FisherAdam C, HuMeng, KozakDarby, WoodErin Leigh, XuXiaoming

Paper Details 
Original Abstract of the Article :
Approval of the first generic 0.05% cyclosporine ophthalmic emulsion (COE) in the U.S. represents a milestone achievement of the science and research program in the U.S. Food and Drug Administration's Center for Drug Evaluation and Research (CDER). COE is a locally acting complex drug product indica...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://doi.org/10.1208/s12248-023-00781-x

データ提供:米国国立医学図書館(NLM)

Generic Cyclosporine Ophthalmic Emulsions: A Milestone in Drug Development

This review highlights the remarkable journey of developing the first generic cyclosporine ophthalmic emulsion (COE) in the United States. It's like finding a hidden oasis in a vast desert, a breakthrough that provides a vital resource for patients. COE is a complex drug used to increase tear production in patients with keratoconjunctivitis sicca, a condition that causes dry eyes. To ensure that the generic COE was equivalent to the original drug, researchers faced a series of challenges, like navigating a complex desert landscape. They used advanced techniques to meticulously analyze the drug's properties and ensure its quality.

A Quality-Driven Approach to Generic Drug Development

The study emphasizes the rigorous process of developing a generic drug, highlighting the importance of quality by design. Researchers meticulously examined the drug's properties, like a skilled desert explorer carefully mapping a new terrain. They employed various techniques to ensure that the generic COE met the same quality standards as the original drug. This meticulous approach ensures that patients receive safe and effective treatment.

Expanding Access to Life-Changing Medications

The review celebrates the approval of the first generic COE, a landmark achievement in drug development. It's like opening a new pathway through the desert, making essential medications more accessible to patients. This development has the potential to improve the lives of countless patients suffering from dry eyes, offering them a much-needed solution.

Dr.Camel's Conclusion

This review demonstrates the dedication and expertise involved in developing generic drugs, a journey as intricate and challenging as navigating a vast desert. The approval of the first generic COE is a testament to the commitment of researchers and regulators to ensure that essential medications are accessible and affordable, bringing a refreshing oasis to those in need.

Date :
  1. Date Completed 2023-01-30
  2. Date Revised 2023-02-22
Further Info :

Pubmed ID

36702976

DOI: Digital Object Identifier

10.1208/s12248-023-00781-x

Related Literature

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.